Integrated Phytochemical Analysis Based on UPLC-Q-TOF-MS/MS, Network Pharmacology, and Experiment Verification to Explore the Potential Mechanism ofPlatycodon grandiflorumfor Chronic Bronchitis

被引:33
|
作者
Deng, Yaling [1 ]
Ren, Hongmin [1 ]
Ye, Xianwen [1 ]
Xia, Lanting [1 ]
Liu, Minmin [1 ]
Liu, Ying [1 ]
Yang, Ming [2 ]
Yang, Songhong [1 ]
Ye, Xide [1 ]
Zhang, Jinlian [1 ]
机构
[1] Jiangxi Univ Tradit Chinese Med, Pharm Coll, Nanchang, Jiangxi, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, Minist Educ, Key Lab Modern Preparat Tradit Chinese Med, Nanchang, Jiangxi, Peoples R China
来源
FRONTIERS IN PHARMACOLOGY | 2020年 / 11卷
基金
中国国家自然科学基金;
关键词
chemical ingredient; chronic bronchitis; experiment verification; mechanism of action; network pharmacology; Platycodon grandiflorum; WEB-SERVER;
D O I
10.3389/fphar.2020.564131
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aim Platycodon grandiflorum(PG) has been widely used for treating chronic bronchitis (CB). However, the material basis and underlying mechanism of action of PG against CB have not yet been elucidated. Methods To analyze the ingredients in PG, ultraperformance liquid chromatography-quadrupole-time-of-flight tandem mass (UPLC-Q-TOF-MS/MS) technology was performed. Subsequently, using data mining and network pharmacology methodology, combined with Discovery Studio 2016 (DS), Cytoscape v3.7.1, and other software, active ingredients, drug-disease targets, and key pathways of PG in the treatment of CB were evaluated. Finally, the reliability of the core targets was evaluated using molecular docking technology andin vitrostudies. Results A total of 36 compounds were identified in PG. According to the basic properties of the compounds, 10 major active ingredients, including platycodin D, were obtained. Based on the data mining approach, the Traditional Chinese Medicine Systems Pharmacology Database, and the Analysis Platform (TCMSP), GeneCards, and other databases were used to obtain targets related to the active ingredients of PG and CB. Network analysis was performed on 144 overlapping gene symbols, and twenty core targets, including interleukin-6 (IL-6) and tumor necrosis factor (TNF), which indicated that the potential signaling pathway that was most relevant to the treatment of CB was the IL-17 signaling pathway. Conclusion In this study, ingredient analysis, network pharmacology analysis, and experiment verification were combined, and revealed that PG can be used to treat CB by reducing inflammation. Our findings provide novel insight into the mechanism of action of Chinese medicine. Furthermore, our data are of value for the research and development of novel drugs and the application thereof.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Based on UPLC-Q-TOF-MS/MS, Systematic Network Pharmacology, and Molecular Docking to Explore the Potential Mechanism of Fructus Aurantii for Major Depression Disorder
    Xie, Yating
    Liu, Ying
    Zheng, Peng
    Zhang, Tao
    Ye, Xianwen
    Liu, Minmin
    Huang, Min
    Wan, Quan
    Zhang, Jinlian
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [2] Exploring potential mechanism of ciwujia tablets for insomnia by UPLC-Q-TOF-MS/MS, network pharmacology, and experimental validation
    Liu, Hongda
    Yang, Le
    Wan, Chunlei
    Li, Zhineng
    Yan, Guangli
    Han, Ying
    Sun, Hui
    Wang, Xijun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Exploration the mechanism of Shenling Baizhu San in the treatment of chronic obstructive pulmonary disease based on UPLC-Q-TOF-MS/MS, network pharmacology and in vitro experimental verification
    Gao, Zu
    Wang, Jiayun
    Lu, Guangying
    Wu, Qiaolan
    Wang, Shijun
    Wu, Xiaolin
    Ou, Chunxue
    Wu, Zhichun
    Yu, Huayun
    Wang, Yuan
    JOURNAL OF ETHNOPHARMACOLOGY, 2024, 324
  • [4] An integrated strategy of UPLC-Q-TOF-MS analysis, network pharmacology, and molecular docking to explore the chemical constituents and mechanism of Zixue Powder against febrile seizures
    Song, Lingling
    Xu, Jian
    Shi, Yanqiong
    Zhao, Hemiao
    Zhang, Min
    Wang, Yuefei
    Cui, Ying
    Chai, Xin
    HELIYON, 2024, 10 (01)
  • [5] Exploring the mechanism of Si-Ni-San against depression by UPLC-Q-TOF-MS/MS integrated with network pharmacology: experimental research
    Jia, Keke
    Li, Changyin
    Xu, Meijuan
    Dai, Guoliang
    Zhou, Jinyong
    Chen, Biqing
    Zou, Jiandong
    Li, Jia
    Zhang, Qingyu
    Ju, Wenzheng
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (01): : 172 - 189
  • [6] Potential hepatoprotective effects of Cistanche deserticola YC Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment
    Wang, Haichao
    Li, Yaying
    Bian, Yifei
    Li, Xue
    Wang, Yubei
    Wu, Ke
    Liu, Chuanguo
    Liu, Yuhong
    Wang, Xiaoming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [7] Based on UPLC-Q-TOF/MS and Network Pharmacology to Explore the Mechanism of Qingre Lishi Decoction in the Treatment of Psoriasis
    Wei, Jingjing
    Liu, Zhaoyang
    Li, Mingming
    Du, Lingyun
    Zhu, Xia
    Leng, Yi
    Han, Changyu
    Xu, Qingqing
    Zhang, Chunhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 3871 - 3889
  • [8] Study on Quality Markers of Poria cocos Based on UPLC-Q-TOF-MS and Network Pharmacology Technology
    Zi LIU
    Na LI
    Zhe LI
    Lanqingqing ZHAO
    Yongzhou YU
    Xiaoyan CUI
    Chunying ZHAO
    Hui XIONG
    Medicinal Plant, 2023, (01) : 12 - 18
  • [9] Integrated UPLC-Q-TOF-MS/MS and Network Pharmacology Approach to Investigating the Metabolic Profile of Marein of Coreopsis tinctoria Nutt.
    Liu, Jing
    Cheng, Xuejing
    Zheng, Xin
    Shi, Yumeng
    Li, Chunxia
    He, Qiaoyu
    Li, Yue
    Chen, Xiaopeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [10] Integrating UPLC-Q-TOF-MS and Network Pharmacology to Explore the Potential Mechanisms of Paeonia lactiflora Pall. in the Treatment of Blood Stasis Syndrome
    Ma, Mengzhen
    Du, Qianqian
    Shi, Suying
    Lv, Jiahui
    Zhang, Wei
    Ge, Dezhu
    Xing, Lihua
    Yu, Nianjun
    MOLECULES, 2024, 29 (13):